紫杉醇涂层球囊与普通球囊治疗功能不良血液透析血管通路的随机对照试验:非申办12个月结果
这项非申办随机试验纳入40例功能不良透析通路患者,比较紫杉醇涂层球囊(DCB)与普通球囊(POBA)的12个月靶病变 primary patency。DCB组6个月(85% vs 55%,P=0.007)和12个月(65% vs 30%,P=0.007)primary patency均显著优于POBA组。
要点
- DCB组12个月primary patency为65%,显著高于POBA组的30%(P=0.007)。
- DCB组6个月primary patency为85%,显著高于POBA组的55%(P=0.007)。
- 两组靶病变狭窄程度和病变长度基线可比(P=0.95和P=0.70)。
核心结论
- 在功能不良动静脉通路中,紫杉醇涂层球囊血管成形术在12个月时提供了显著更好的primary patency。
研究设计与样本
- 非申办随机对照试验,单中心,纳入40例功能不良透析通路患者,随机分配至In.Pact Admiral紫杉醇DCB组或POBA组。
- 患者、血透工作人员和超声技师对治疗分组设盲,按监测方案随访。
主要发现
- DCB组6个月primary patency为85%,POBA组为55%(P=0.007)。
- DCB组12个月primary patency为65%,POBA组为30%(P=0.007)。
- 两组平均年龄分别为58岁和57岁,人口学参数可比。
- 靶病变位置(吻合口旁和动静脉吻合口、穿刺部位、瘘管/移植物)两组可比。
- 平均靶病变狭窄DCB组为69.8±15.8%,POBA组为69.5±13.6%(P=0.95);病变长度DCB组为45.8±38.4 mm,POBA组为50.2±33.5 mm(P=0.70)。
临床怎么用
- 对于功能不良的血液透析动静脉通路,可考虑使用紫杉醇涂层球囊血管成形术以改善12个月primary patency。
局限性
- 单中心、样本量40例,结果需更大规模多中心试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plain balloon angioplasty is regarded as the mainstay of treatment for failing vascular access with high success rate, but the poor treatment durability creates significant workload and increases patient morbidity. The study aims to compare target lesion primary patency rate at 12 months between paclitaxel-coated balloon (DCB) versus plain old balloon angioplasty (POBA) for treatment of dysfunctional vascular access. METHODS: This nonsponsored-randomized trial enrolled 40 patients with dysfunctional dialysis access at a single center. Patients were randomized into In.Pact Admiral Paclitaxel DCB or POBA after lesion crossing regardless of lesion type. Patients are followed up under surveillance protocol. Patients, hemodialysis staff, and sonographer are blinded to the treatment arms. Twelve-month primary patency rate in both arms are evaluated. RESULTS: 40 patients were recruited since June 2016 and were allocated to the DCB or POBA group. The mean age is 58 and 57 years with comparable demographic parameters. The locations of target lesion were comparable in both groups (juxta and arteriovenous anastomosis, cannulation site, and fistula/graft), with similar mean target lesion stenosis 69.8 +/- 15.8% for DCB and 69.5 +/- 13.6% for POBA (P = 0.95), and the lesion length for DCB is 45.8 +/- 38.4 mm and 50.2 +/- 33.5 mm for POBA (P = 0.70). Patients in DCB performed significantly better in terms of primary patency at 6 months 85% versus 55% (P = 0.007). The superiority in primary patency in DCB group exists at 12 months 65% versus 30% (P = 0.007). CONCLUSIONS: Paclitaxel balloon angioplasty approach provides significant better primary patency in dysfunctional arteriovenous access at 12 months in our nonsponsored-randomized trial.
引用
- Pang SYC, Au-Yeung KCL, Liu GYL, et al. Randomized Controlled Trial for Paclitaxel-coated Balloon versus Plain Balloon Angioplasty in Dysfunctional Hemodialysis Vascular Access: 12-month Outcome from a Nonsponsored Trial. Ann Vasc Surg. 2020. PMID: 33221299. doi:10.1016/j.avsg.2020.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。